1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hunan Nucien Pharmaceutical Co. Ltd. Class A

Hunan Nucien Pharmaceutical Co. Ltd. Class A

SSSE:688189
5.96
CNY
-0.14
(-2.30%)
1.64BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.87
0.98
3.41
4.93
7.84
5.27
3.57
2.39
0.92
0.52
- -
Basic EPS, GAAP
0.05
0.08
0.26
0.44
0.97
-1.17
-0.4
-0.08
-1.26
-0.5
- -
Free Cash Flow per Basic Share
0.12
0.07
0.21
0.1
-2.43
-1.26
-1.03
0.67
-0.21
0.13
- -
Dividend per Share
0.16
0.04
0.07
0.08
0.1
0.4
0.08
0.06
0.02
0.01
- -
Book Value per Share
0.37
0.88
1.14
1.62
5.82
5.07
4.79
4.71
3.41
2.86
2.84
Tangible Book Value per Share
0.06
0.27
0.58
1.11
5.42
4.3
4.08
3.99
2.61
2.1
2.05
Basic Weighted Avg Shares
318
355
206
206
131
140
196
274
274
274
272
Sales/Revenue/Turnover
278
348
701
1,014
1,029
738
699
655
252
142
- -
Operating Margin (%)
15.13
14.73
11.09
13.28
15.67
-11.89
9.24
6.35
-30.46
-55.13
- -
Depreciation Expense
31
34
40
37
35
38
48
37
38
36
- -
Net Income, GAAP
15
27
54
91
128
-163
-77
-21
-347
-137
- -
Effective Tax Rate (%)
16.77
0.46
2.4
11.89
0.09
- -
- -
- -
- -
- -
- -
Profit Margin (%)
5.25
7.81
7.64
9.02
12.43
-22.11
-11.08
-3.25
-137.65
-96.46
- -
Working Capital
-124
-155
1
108
1,332
937
848
832
438
306
301
LT Debt
99
62
135
110
76
55
3
1
- -
- -
- -
Total Equity
171
202
265
357
1,619
1,392
1,296
1,274
878
712
710
Return on Invested Capital (%)
- -
7.55
10.93
15.07
10
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
6.25
11.15
15.68
10.14
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
16.24
25.79
32.27
13.27
-10.93
-5.72
-1.63
-31.08
-15.92
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10
10
60
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
274
274
274
Market Capitalization
2,187
2,099
1,641

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
400
376
442
Cash, Cash Equivalents & STI
302
278
347
Accounts Receivable, Net
36
30
15
Inventories
36
42
34
Total Current Liabilities
94
89
141
Payables & Accruals
- -
- -
- -
ST Debt
10
10
60
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-14.52%
-18.89%
Free Cash Flow
- -
-102.81%
-160.97%
Net Income, GAAP
- -
223.23%
-60.49%
Sales/Revenue/Turnover
- -
-29.01%
-43.62%
Total Cash Common Dividend
- -
25.5%
-48.2%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
136
79
36
1
252
2025
41
21
- -
59
142
2026
26
30
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
- -
-0.25
-1.09
-1.26
2025
-0.03
-0.12
- -
-0.25
-0.5
2026
-0.05
-0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.02
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Full Time Employees
302
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Guangzhou China
IPO Date
Mar 26, 2020
Website
nucien.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hunan Nucien Pharmaceutical Co. Ltd. is a China-based pharmaceutical enterprise specializing in the research, development, manufacturing, and commercialization of chemical drugs, active pharmaceutical ingredients, and modern therapeutic preparations. Founded in 2006 and headquartered in Changsha, Hunan Province, the company operates primarily within the anti-infective, cardiovascular, cerebrovascular, anti-tumor, and chronic disease therapeutic areas, supplying public hospital networks, healthcare institutions, and retail pharmaceutical distributors throughout mainland China. The company offers an extensive portfolio of prescription drugs and formulations, including: anti-infective and antiviral agents, led by Peramivir Sodium Chloride Injection for influenza, Cefuroxime Axetil tablets and dispersible tablets, Cefazolin Sodium for injection, Cefodizime Sodium, and Azithromycin; cardiovascular and metabolic disease medications, comprising Captopril sustained-release tablets, Simvastatin tablets, Trimetazidine Hydrochloride, Metformin Hydrochloride sustained-release tablets, and Ginkgo Biloba extract preparations; gastrointestinal therapies, featuring Omeprazole enteric-coated capsules, Rabeprazole Sodium, and Mosapride Citrate; and anti-tumor therapeutics, specialty active pharmaceutical ingredients, and customized contract development and manufacturing services for third-party pharmaceutical partners. In recent major developments, the company has advanced its innovative drug pipeline by progressing clinical trials for next-generation oral anti-influenza candidates and small-molecule targeted anti-tumor compounds; expanded its commercial scale by securing key product listings under China's National Centralized Drug Procurement framework; adapted its corporate structure and strategic growth initiatives following restructuring within provincial state-owned asset platforms; and invested in the technical upgrade and capacity expansion of its intelligent manufacturing bases to enhance compliance and supply chain resilience.